Pilot Proof of Concept Study of NBMI Treatment of Mercury Intoxication
A Randomized, Placebo-controlled Study to Explore Safety, Dose and Efficacy of NBMI in a Mercury Intoxicated Population
  • Phase

    Phase 2
  • Study Type

  • Status

    Completed No Results Posted
  • Intervention/Treatment

    emeramide ...
  • Study Participants

A randomized, placebo controlled, double blind proof of concept study of NBMI in treatment of mercury intoxication.
The objectives of this study are to evaluate the efficacy and safety of two doses of NBMI compared to placebo in mercury intoxicated patients.
Study Started
Aug 31
Primary Completion
Jan 31
Study Completion
Apr 30
Last Update
Mar 08

Drug Emeramide

Mercury chelator NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide)

  • Other names: NBMI, Irminix

Drug Placebo

NBMI Placebo

NBMI (Emeramide) 100mg Experimental

NBMI oral capsules 100mg administered once daily. Double dummy used for blinding i.e. 2 x 50mg NBMI + 1 x 200mg placebo capsule equals in total 3 capsules administered daily.

NBMI (Emeramide) 300mg Experimental

NBMI oral capsules 300mg administered once daily. Double dummy used for blinding i.e. 2 x 50mg NBMI + 1 x 200mg NBMI capsule equals in total 3 capsules administered daily.

Placebo Placebo Comparator

Placebo oral capsules administered once daily. Double dummy used for blinding i.e. 2 x 50mg size + 1 x 200mg size placebo capsules equal in total 3 capsules administered daily.


Inclusion criteria

Male or female subjects, age between 18 and 65 years, inclusive.
Urine-Hg ≥ 15 μg/L.
Mercury intoxication medical score sum (Doering et al. 2014) ≥ 5 or medical score sum ≥ 3 in combination with at least two of the following symptoms; social nervousness/withdrawal, irritability, memory loss, metallic taste, mental- and physical fatigue.
Has signed informed consent for participation.
Willingness and ability to comply with study procedures, visit schedules, and other instructions regarding the study.

Exclusion criteria

History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subjects at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
Known or a medical history of renal disorder, significant renal failure, or high risk of renal failure.
Any clinically significant abnormalities in clinical chemistry or haematology results at the time of screening as judged by the investigator.
Known or suspected neurodegenerative disorder including but not limited to stroke, polio, Parkinson's and Alzheimer's disease.
Known or suspected drug or alcohol abuse.
Positive pregnancy test in women.
Serious bacterial and chronic viral infection such as human immunodeficiency virus (HIV) or hepatitis virus.
History of severe allergy/hypersensitivity or on-going allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to NBMI.
History of allergy/hypersensitivity to bisulphites (e.g. red/white wine).
Participation in any other clinical study that included drug treatment within three months of the first administration of investigational product.
Use of other therapies for mercury intoxication including metal chelators within three months.
Investigator considers subject unlikely to comply with study procedures, restrictions and requirements.
No Results Posted